Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1302-1311

  Gonçalves, Naiane do Nascimento ^a,b   Rodrigues, Rodrigo Ventura ^a,c   Jardim Perassi, Bruna Victorasso ^a,c   Moschetta, Marina Gobbe ^a,b   Lopes, Juliana Ramos ^a,c   Colombo, Jucimara ^a   de Campos Zuccari, Debora Aparecida Pires ^a,b  

^a Laboratório de Investigação Molecular no Câncer LIMC   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cell lines; HIF 1 ; Melatonin; Oral cancer; ROCK 1; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELATONIN; MOLECULAR MARKER; RHO KINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; ROCK1 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; METASTASIS; MOUTH CARCINOMA; MTT ASSAY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELATONIN; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RHO-ASSOCIATED KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911469827     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140812110246     Document Type: Article

References (59)

1. Kademani, D. Oral cancer. Mayo Clin. Proc., 2007, 82, 878-887.
2. Lambert, R.; Sauvaget, C.C.C.M.; Sankaranarayanan, R. Epidemiology of cancer from the oral cavity and oropharynx. Eur. J. Gastroenterol. Hepatol., 2011, 23, 633-641.
3. Chin, D.; Boyle, G.M.; Porceddu, S.; Theile, D.R.; Parsons, P.G.; Coman, W.B. Head and neck cancer: Past, present and future. Expert. Ver. Anticancer Ther., 2006, 6, 1111-1118.
4. Pérez-Sayáns, M.; Suárez-Peñaranda, J.M.; Pilar, G.D.; Barros-Angueira, F.; Gándara-Rey, J.M.; García-García, A. Hypoxia-inducible factors in OSCC. Cancer Lett., 2011, 26, 1-8.
5. Kang F.W.; Que L.; Wu, M.; Wang, Z.L.; Sun, J. Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol. Rep., 2012, 28, 193-199.
6. Liu, S.Y.; Chang, L.C.; Pan, L.F.; Hung, Y.J.; Lee, C.H.; Shieh, Y.S. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol., 2008, 44, 277-285.
7. Eckert, A.W.; Kappler, M.; Schubert, J.; Taubert, H. Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac. Surg., 2012, 16, 189-196.
8. Naruse, T.; Kawasaki, G.; Yanamoto, S.; Mizuno, A.; Umeda, M. Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: Correlation with the mTOR-HIF-1α pathway. Anticancer Res., 2011, 12, 4429-4437.
9. Zhao, S.F.; Yang, X.D.; Lu, M.X.; Sun, G.W.; Wang, Y.X.; Zhang, Y.K.; Pu, Y.M.; Tang, E.Y. Prognostic significance of VEGF immunohistochemical expression in oral cancer: A meta-analysis of the literature. Tumour Biol., 2013, 34, 3165-3171.
10. Islam, M.; Sharma, S.; Kumar, B.; Teknos, T.N.; Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol., 2013, 8, 778-786.
11. Shi, J.; Wei, L. Rho kinase in the regulation of cell death and survival. Arch Immunol. Ther. Exp. (Warsz), 2007, 55, 61-75.
12. Patel, R.A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S.M. Identification of novel ROCK-1 inhibitors with anti-migratory and anti-invasive activities. Oncogene, 2014, 33, 550-555.
13. Kaneko, K.; Satoh, K.; Masamune, A.; Satoh, A.; Shimosegawa, T. Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pancreas, 2002, 24, 251-257.
14. Kamai, T.; Tsujii, T.; Arai, K.; Takagi, K.; Asami, H.; Ito, Y.; Oshima, H. Significant association of Rho/ROCK-1 pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res., 2003, 9, 2632-2641.
15. Raviraj, V.; Fok, S.; Zhao, J.; Chien, H.Y.; Lyons, J.G.; Thompson, E.W.; Soon, L. Regulation of ROCK-1 via Notch1 during breast cancer cell migration into dense matrices. BMC Cell Biol., 2012, 13, 12.
16. Vigil, D.; Kim, T.Y.; Plachco, A.; Garton, A.J.; Castaldo, L.; Pachter, J.A.; Dong, H.; Chen, X.; Tokar, B.; Campbell, S.L.; Der, C.J. ROCK-1 and ROCK-2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res., 2012, 72, 5338-5347.
17. Lane, J.; Martin, T.A.; Watkins, G.; Mansel, R.E.; Jiang, W.G. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int. J. Oncol., 2008, 33, 585-593.
18. Liu, S.; Goldstein, R.H.; Scepansky, E.M.; Rosenblatt, M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res., 2009, 69, 8742-8751.
19. Luchetti, F.; Canonico, B.; Betti, M.; Arcangeletti, M.; Pilolli, F.; Piroddi, M.; Canesi, L.; Papa, S.; Galli, F. Melatonin signaling and cell protection function. FASEB J., 2010, 24, 3603-3624.
20. Cutando, A.; López-Valverde, A.; Arias-Santiago, S.; Vicente, D.E.J.; Dieg, D.E.K.G. Role of melatonin in cancer treatment. Anticancer Res., 2012, 32, 2747-2753.
21. Di Bella, G.; Mascia, F.; Gualano, L.; Di Bella, L. Melatonin anticancer effects: Review. Int. J. Mol. Sci., 2013, 24, 2410-2430.
22. Park, J.W.; Hwang, M.S.; Suh, S.I.; Baek, W.K. Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J. Pineal Res., 2009, 46, 415-421.
23. Zhang, Y.; Liu, Q.; Wang, F.; Ling, E.A.; Liu, S.; Wang, L.; Yang, Y.; Yao, L.; Chen, X.; Wang, F.; Shi, W.; Gao, M.; Hao, A. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1α. J. Pineal Res., 2013, 55, 121-130.
24. Alvarez-García, V.; González, A.; Alonso-González, C.; Martínez-Campa, C.; Cos, S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J. Pineal Res., 2013, 54, 373-380.
25. Lv, D.; Cui, P.L.; Yao, S.W.; Xu, Y.Q.; Yang, Z.X. Melatonin inhibits the expression of vascular endothelial growth factor in pancreatic cancer cells. Chin. J. Cancer Res., 2012, 24, 310-316.
26. Carbajo-Pescador, S.; Ordoñez, R.; Benet M.; Jover, R.; García-Palomo, A.; Mauriz, J.L.; González-Gallego, J. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br. J. Cancer., 2013, 109, 83-91.
27. Ramírez-Rodríguez, G.; Ortiz-López, L.; Benítez-King, G. Melatonin increases stress fibers and focal adhesions in MDCK cells: participation of Rho-associated kinase and protein kinase C. J. Pineal Res., 2007, 42, 180-190.
28. Ortíz-López, L.; Morales-Mulia, S.; Ramírez-Rodríguez, G.; Benítez-King, G. ROCK-1 regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. J. Pineal Res., 2009, 46, 15-21.
29. Gómez-Moreno, G.; Guardia, J.; Ferrera, M.J.; Cutando, A.; Reiter, R.J. Melatonin in diseases of the oral cavity. Oral Dis., 2010, 16, 242-247.
30. Rheinwald, J.G.; Beckett, M.A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res., 1981, 41, 1657-1663.
31. Dai, M.; Cui, P.; Yu, M. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J. Pineal Res., 2008, 44, 121-126.
32. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T). Method. Nat. Protoc., 2008, 6, 1101-1108.
33. Agostini, M.; Silva, S.D.; Zecchin, K.G.; Coletta, R.D.; Jorge, J.; Loda, M.; Graner, E. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol., 2004, 40, 728-735.
34. López de Cicco, R.; Bassi, D.E.; Page, R.; Klein-Szanto, A.J. Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology. Acta Odontol. Latinoam., 2004, 15, 29-37.
35. López de Cicco, R.; Bassi, D.E.; Page, R.; Klein-Szanto, A.J. Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology. Acta Odontol. Latinoam., 2004, 15, 29-37.
36. Fan, L.L.; Sun, G.P.; Wei, W.; Wang, Z.G.; Ge, L.; Fu, W.Z.; Wang, H. Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J. Gastroenterol., 2010, 16, 1473-1481.
37. Margheri, M.; Pacini, N.; Tani, A.; Nosi, D.; Squecco, R.; Dama, A.; Masala, E.; Francini, F.; Zecchi-Orlandini, S.; Formigli, L. Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. Eur. J. Pharmacol., 2012, 681, 34-43.
38. Zhang, S., Qi, Y.; Zhang, H.; He, W.; Zhou, Q.; Gui, S.; Wang, Y. Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line. Biotech. Histochem., 2012, 88, 281-289.
39. Sainz, R.M.; Mayo, J.C.; Rodriguez, C.; Tan, D.X.; Lopez-Burillo, S.; Reiter, R.J. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. Cell Mol. Life Sci., 2003, 60, 1407-1426.
40. Martins, E.J.R.; Fernandes, L.C.; Bartol, I.; Cipolla-Neto, J.; Costa Rosa, L.F. The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumour-bearing rats. J. Neuroimmunol., 1998, 82, 81-89.
41. Cutolo, M.; Villaggio, B.; Candido, F. Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. Ann. NY Acad. Sci., 1999, 876, 246-254.
42. Maestroni, G.J.; Sulli, A.; Pizzorni, C.; Villaggio, B.; Cutolo, M. Melatonin in rheumatoid arthritis: Synovial macrophages show melatonin receptors. Ann. N. Y. Acad. Sci., 2002, 966, 271-275.
43. Mei, Q.; Yu, J.P.; Xu, J.M.; Wei, W.; Xiang, L.; Yue, L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol. Sin., 2002, 23, 882-886.
44. Xia, M.Z.; Liang, Y.L.H.; Chen, X.; Huang, Y.Y.; Zhang, Z.H.; Chen, Y.H.; Zhang, C.; Zhao, M.; Xu, D.X.; Song, L.H. Melatonin modulates TLR4-mediated inflammatory genes through MyD88-and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J. Pineal Res., 2012, 53, 325-334.
45. Park, S.Y.; Jang, W.J.; Yi, E.Y.; Jang, J.Y.; Jung, Y.; Jeong, J.W.; Kim, Y.J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J. Pineal Res., 2010, 48, 178-184.
46. Vaupel, P. The role of hypoxia-induced factors in tumor progression. Oncologist, 2004, 9, 10-17.
47. Alvarez-García, V.; Gonzáles, A.; Alonso-González, C.; Martínez-Campa, C.; Cos, S. Antiangiogenic effects of melatonina in endotelial cell cultures. Microvsc. Res., 2013, 87, 25-33.
48. Spencer, C.; Montalvo, J.; Sarah, R.; Mclaughlin, S.R.; Bryan, B.A. Small molecule inhibition of cytoskeletal dynamics in melanoma tumors results in altered transcriptional expression patterns of key genes involved in tumor initiation and progression. Cancer Genom. Proteom., 2011, 8, 77-85.
49. Somlyo, A.V.; Bradshaw, D.; Ramos, S.; Murphy, C.; Myers, C.E.; Somlyo, A.P. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun., 2000, 269, 652-659.
50. Rattan, R.; Giri, S.; Singh, A.K.; Singh, I. Rho/ROCK-1 pathway as a target of tumor therapy. J. Neurosci. Res., 2006, 83, 243-255.
51. Liu, X.; Choy, E.; Hornicek, F.J.; Yang, S.; Yang, C.; Harmon, D.; Mankin, H.; Duan, Z. ROCK-1 as a potential therapeutic target in osteosarcoma. J. Orthop. Res., 2011, 29, 1259-1266.
52. Yang, X.; Di, J.; Zhang, Y.; Zhang, S.; Lu, J.; Liu, J.; Shi, W. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed. Pharmacother., 2012, 66, 221-227.
53. Saito, K.; Sakaguchi, M.; Lioka, H.; Matsui, M.; Nakanishi, H.; Huh, N.H.; Kondo, E. Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells. Oncogene, 2013, 33, 1274-1286.
54. Jeon, G.A.; Lee, J.S.; Patel, V.; Gutkind, J.S.; Thorgeirsson, S.S.; Kim, E.C.; Chu, I.S.; Amornphimoltham, P.; Park, M.H. Global gene expression profiles of human head and neck squamous carcinoma cell lines. Int. J. Cancer, 2004, 112, 249-258.
55. Cengiz, M.I.; Cengiz, S.; Wang, H.L. Melatonin and oral cancer. Int. J. Den., 2012, 2012, 491872.
56. Cutando, A.; Aneiros-Fernández, J.; López-Valverde, A.; Arias-Santiago, S.; Aneiros-Cachaza, J.; Reiter, R.J. A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. Arch. Oral Biol., 2011, 56, 944-950.
57. Nakamura, E.; Kozaki, K.; Tsuda, H.; Suzuki, E.; Pimkhaokham, A.; Yamamoto, G.; Irie, T.; Tachikawa, T.; Amagasa, T.; Inazawa, J.; Imoto, I. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci., 2008, 99, 1390-1400.
58. Jablonska, K.; Pula, B.; Zemla, A.; Owczarek, T.; Wojnar, A.; Rys, J.; Ambicka, A.; Podhorska-Okolow, M.; Ugorski, M.; Dziegiel, P. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J. Pineal Res., 2013, 54, 334-345.
59. Qiao, B.; Newell, W.; Johnson, N.W.; Gao, J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-ß1 is Snail family dependent and correlates with matrix metalloproteinase-2 and -9 expression. Int. J. Oncol., 2010, 37, 663-668.